

## ASX ANNOUNCEMENT

9 November 2023

# Correction of Defective Cleansing Notice



1. On 27 September 2023, Little Green Pharma Ltd (**the Company**) issued a cleansing notice in respect of 277,777 shares (**Director Shares**) issued to the Company's Managing Director, Fleta Solomon (**Director Shares**) and 72,500 shares (**Consultant Shares**) issued to Zero Nominees Pty Ltd pursuant to a services agreement between the Company and Report Card Pty Ltd t/a Advisir (**Cleansing Notice**). The Director Shares and Consultant Shares were issued on 27 September 2023 and the Company made an application to ASX for the quotation of those shares on that same date.
2. The Company advises that the Cleansing Notice is defective as the Company was not in a position to issue a notice under s 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) as, at the time of given the Cleansing Notice, the Company was not in compliance with the provisions of Chapter 2M of the Act as they applied to the Company (further details are provided below).
3. Following the resignation of Deloitte Touche Tohmatsu as the Company's auditor, the Company appointed BDO Audit (WA) Pty Ltd (**BDO**) as its auditors with effect from 25 October 2022. In accordance with section 327C(2) of the Act, BDO's appointment ceased at the Company's next annual general meeting, which was held on 29 August 2023. The Company should have sought shareholder approval for the appointment of BDO as its auditor under section 327B(1)(b) at the annual general meeting. The Company inadvertently did not seek this shareholder approval.
4. The non-compliance with the Act relates to an administrative oversight and the Company wishes to assure shareholders that it acted promptly to rectify the oversight upon becoming aware the Cleansing Notice was defective.
5. Upon becoming aware the Cleansing Notice was defective, the Company contacted Ms Solomon and Zero Nominees Pty Ltd (together, the **Affected Parties**) and following receipt of each of their consent, the Company entered into a voluntary restriction deed with each Affected Party and pursuant to the restriction deed, the Company applied a holding lock to the Director Shares and Consultant Shares which precludes the Affected Party on-selling the relevant shares.

6. The Company confirms that no Director Shares and Consultant Shares have been on-sold and that other than the Director Shares and Consultant Shares, the Company confirms that no other shares were issued and subsequently cleansed under the defective Cleansing Notice.
7. The Company will shortly convene a general meeting in order to seek shareholder approval to appoint BDO as auditor of the Company. If shareholders approve the appointment of BDO as auditor, the Company will need to re-seek shareholder approval at its 2024 annual general meeting to appoint BDO as auditor of the Company in accordance with the requirements of sections 327B(1) and 327C(2) of the Act.
8. This announcement is given pursuant to and in accordance with s 708A(9)(c) of the Act.

**ENDS  
BY ORDER OF THE BOARD**



**Alistair Warren**  
Company Secretary

For further information please contact:

**Alistair Warren**  
**Company Secretary**  
Little Green Pharma  
E: [cosec@lgp.global](mailto:cosec@lgp.global)  
T: +61 8 6280 0050

**Paul Long**  
**Chief Executive Officer**  
Little Green Pharma  
E: [p.long@lgp.global](mailto:p.long@lgp.global)  
T: +61 8 6280 0050



## About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, with its Danish facility being one of the largest GMP medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)